Novartis
Signal active
Investment Firm
Overview
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Their mission is to discover new ways to improve and extend people's lives.
They apply their expertise in science and innovation to society’s biggest health challenges. Responsibility is a core part of their business strategy.
Highlights
Founded
1996
Industry
Biotechnology
Employees
10001+
Investment
75
Lead Investment
15
Exits
21
Stages
Late Stage Venture, Early Stage Venture, Seed
Investor Type
N/A
Location
Basel, Basel-Stadt, Switzerland, Europe
Contact Information
Social
Profile Resume
Novartis, established in 1996 and headquartered in Switzerland, Europe., specializes in Late Stage Venture, Early Stage Venture, Seed investments across Mobile, Health Care, Pharmaceutical, Medical, Enterprise Software, Information Technology, Software, SaaS, Data Management, Data Governance. The organization boasts a portfolio of 73 investments, with an average round size of $106.5M and 21 successful exits. Their recent investments include Proteus Digital Health, Oracle, Raze Therapeutics, Atlas Venture, MPM Capital. The highest investment round they participated in was $571.5B. Among their most notable exits are Proteus Digital Health and Oracle. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
Novartis has made 75 investments. Their most recent investment was on Jul 24, 2024, when Dren Bio raised $25.0M.
Novartis has made 15 diversity investments. Their most recent diversity investment was on Jun 06, 2023, when RxLightning raised $17.5M.
investments
75
Diversity investments
15
Lead investments
15
Number of exits
21
Investments
75
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Sep 25, 2023 | Northern Yiheng | Manufacturing | null |
| Dec 05, 2023 | Yseop | Software | null |
| Jul 16, 2024 | - | - | 150.0M |
| Jul 24, 2024 | Dren Bio | Biotechnology | 25.0M |
Exits
21
Funding Timeline
Funding rounds
75
Investors
1
Funds
0
Funding Rounds
75
Novartis has raised 75 rounds. Their latest funding was raised on Jul 24, 2024 from a Corporate Round - Dren Bio round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Sep 25, 2023 | Series B - Northern Yiheng | - | 0 | - |
| Dec 05, 2023 | Venture Round - Yseop | - | 0 | - |
| Jul 16, 2024 | Series D - CatalYm | - | 150.0M | - |
| Jul 24, 2024 | Corporate Round - Dren Bio | - | 25.0M | - |
Investors
2
Novartis is funded by 2 investor(s). Bill & Melinda Gates Foundation Kantor is the most recent investors.
| Investor Name | Lead Investor | Funding Round | Money Raised |
|---|---|---|---|
Bill & Melinda Gates Foundation | Yes | Grant - Novartis | 6.5M |
| - | No | Post-IPO Debt - Novartis | 2487.7M |
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
News
Sep 24, 2024
FierceBiotech - Novartis inks $1B-plus biobucks deal with Flagship's Generate
News
Sep 24, 2024
Endpoints News - Flagship’s AI biotech Generate lands $65M upfront in Novartis deal, as first clinical readouts near
News
Sep 24, 2024
Business Wire - Generate:Biomedicines Announces Multi-Target Collaboration with Novartis to Discover and Develop Protein Therapeutics with Generative AI
News
Sep 21, 2024
SeekingAlpha - Novartis' Pluvicto expected to dominate prostate cancer radiopharmaceutical market
News
Sep 20, 2024
thefly.com - Firefly Neuroscience collaborates with Takeda, Novartis
News
Sep 20, 2024
MarketScreener - Novartis AG : There is still some upside potential